{"id":"https://openalex.org/W4367296293","doi":"https://doi.org/10.1212/wnl.0000000000202155","title":"Neuropathy as an adverse effect of proteasomal inhibitors in multiple myeloma treatment: a network meta-analysis (P11-8.004)","display_name":"Neuropathy as an adverse effect of proteasomal inhibitors in multiple myeloma treatment: a network meta-analysis (P11-8.004)","publication_year":2023,"publication_date":"2023-04-25","ids":{"openalex":"https://openalex.org/W4367296293","doi":"https://doi.org/10.1212/wnl.0000000000202155"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000202155","doi":"https://doi.org/10.1212/wnl.0000000000202155","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000202155","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030795281","display_name":"Anisha Garg","orcid":"https://orcid.org/0000-0002-9267-4728","observed_orcids":["https://orcid.org/0000-0002-9267-4728"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anisha Garg","raw_affiliation_strings":["Yale University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102995996","display_name":"Avash Das","orcid":"https://orcid.org/0000-0002-3624-9495","observed_orcids":["https://orcid.org/0000-0002-3624-9495"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Avash Das","raw_affiliation_strings":["UT Southwestern"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Southwestern","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088819471","display_name":"Subhajit Dasgupta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Subhajit Dasgupta","raw_affiliation_strings":["UT Southwestern"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Southwestern","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026574827","display_name":"Shaji Kunnathu Kumar","orcid":"https://orcid.org/0000-0001-5392-9284","observed_orcids":["https://orcid.org/0000-0001-5392-9284"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaji Kumar","raw_affiliation_strings":["Mayo Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073326828","display_name":"Bhaskar Roy","orcid":"https://orcid.org/0000-0003-3604-6310","observed_orcids":["https://orcid.org/0000-0003-3604-6310"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bhaskar Roy","raw_affiliation_strings":["Yale University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University","institution_ids":["https://openalex.org/I32971472"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.07483649,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"100","issue":"17_supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9146000146865845,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9146000146865845,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.07599999755620956,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuropathy","display_name":"neuropathy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9750000238418579},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":0.9729999899864197},{"id":"https://openalex.org/keywords/ixazomib","display_name":"ixazomib","score":1.0},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7760000228881836},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.9440000057220459}],"concepts":[{"id":"https://openalex.org/C2781098529","wikidata":"https://www.wikidata.org/wiki/Q20948663","display_name":"Ixazomib","level":5,"score":0.8825149536132812},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8705506324768066},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.8649563193321228},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7787370681762695},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6261399984359741},{"id":"https://openalex.org/C2779901536","wikidata":"https://www.wikidata.org/wiki/Q945238","display_name":"Peripheral neuropathy","level":3,"score":0.6021801829338074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5941599011421204},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.5174825191497803},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5049393773078918},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.500952959060669},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43442967534065247},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3467417359352112},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.0},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000202155","doi":"https://doi.org/10.1212/wnl.0000000000202155","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000202155","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8199999928474426,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1850271161","https://openalex.org/W2987448391","https://openalex.org/W2983482650","https://openalex.org/W3184357652","https://openalex.org/W2592226531","https://openalex.org/W2269989009","https://openalex.org/W4210810123","https://openalex.org/W2513567932","https://openalex.org/W4288751912","https://openalex.org/W2394791231"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"determine":[2],"the":[3,48,121,130,144,149,168,172,237,265,324,343,362],"comparative":[4],"risk":[5,245,267],"of":[6,8,52,62,68,74,132,161,174,179,246,268,286,326,345,364,383],"incidence":[7,173],"neuropathy":[9,69,88,133,216,248,269],"associated":[10,34,241,263],"with":[11,35,97,111,158,230,242,260,264,289],"proteasomal":[12],"inhibitors":[13],"(PIs)":[14],"in":[15,28,89,120,167,205,272,323,342,361,377],"multiple":[16],"myeloma":[17],"(MM)":[18],"patients.":[19,274],"Background:":[20],"PIs":[21,76,107,271],"(bortezomib,":[22],"carfilzomib,":[23],"ixazomib)":[24],"are":[25],"commonly":[26],"used":[27,109],"treating":[29,281],"MM.":[30],"Bortezomib":[31],"is":[32,262],"traditionally":[33],"peripheral":[36],"neuropathy,":[37],"but":[38],"it":[39],"remains":[40],"unclear":[41],"whether":[42],"its":[43],"adverse":[44],"effects":[45],"also":[46],"mirror":[47],"class-specific":[49],"neurotoxic":[50],"profile":[51],"PIs.":[53],"Newer":[54],"oral":[55],"proteasome":[56],"inhibitor,":[57],"ixazomib,":[58],"has":[59,77,295,301,307,313,319,338,357,375,386],"fewer":[60],"incidences":[61],"neuropathy.":[63],"However,":[64],"a":[65,71,159,191,202,243,331,350,369],"direct":[66],"comparison":[67],"as":[70,330,349,368],"side":[72],"effect":[73],"individual":[75],"not":[78],"been":[79],"performed.":[80],"Design/Methods:":[81],"Published":[82],"randomized":[83,155],"control":[84,192],"trials":[85,157],"(RCTs)":[86],"reporting":[87],"MM":[90,163,273],"patients":[91,164,228,287],"(newly":[92],"diagnosed":[93],"and/or":[94],"relapsed)":[95],"treated":[96,229,288],"PI":[98,232],"were":[99,108,124,141,165],"searched":[100],"up":[101],"to":[102,147,198,234,297,303,309,315],"May":[103],"2021.":[104],"Studies":[105],"where":[106],"along":[110],"chemotherapy":[112],"vs.":[113],"placebo,":[114],"or":[115],"no":[116],"additional":[117],"drugs":[118],"(control)":[119],"other":[122],"arm":[123],"included.":[125],"The":[126,381],"primary":[127],"outcome":[128],"was":[129,201,240],"presence":[131],"after":[134],"follow-up.":[135],"Pair-wise":[136],"meta-analysis":[137,140],"and":[138,185,214,283],"network":[139],"performed":[142],"using":[143],"frequentist\u2019s":[145],"approach":[146],"estimate":[148],"odds":[150],"ratio":[151],"(OR).":[152],"Results:":[153],"Eleven":[154],"clinical":[156],"total":[160,178],"3576":[162],"evaluated":[166],"analysis,":[169],"which":[170],"reported":[171,187],"neuropathic":[175,188],"events.":[176],"A":[177],"nine":[180],"studies":[181,195],"on":[182,218],"bortezomib(6),":[183],"ixazomib(2),":[184],"carfilzomib(1)":[186],"events":[189],"against":[190],"group.":[193],"Two":[194],"compared":[196,233],"bortezomib":[197,239,261],"carfilzomib.":[199],"There":[200],"significant":[203],"increase":[204],"all":[206],"grade":[207],"(OR":[208,221,249],"=":[209,222],"2.51,":[210],"95%":[211,224,251],"CI":[212,225,252],"1.54\u20134.09)":[213],"high-grade":[215],"(based":[217],"CTCAE":[219],"criteria)":[220],"3.37,":[223],"2.36\u20134.81)":[226],"among":[227,270,280],"any":[231],"control.":[235],"Among":[236],"PIs,":[238],"maximum":[244],"all-grade":[247],"4.00;":[250],"3.30\u20134.85).":[253],"Conclusions:":[254],"Our":[255],"results":[256],"showed":[257],"that":[258],"treatment":[259],"highest":[266],"This":[275],"may":[276],"warrant":[277],"increased":[278],"awareness":[279],"physicians":[282],"close":[284],"monitoring":[285],"these":[290],"agents.":[291],"Disclosure:":[292],"Dr.":[293,317,336,355,373,384],"Garg":[294],"nothing":[296,302,308,314],"disclose.":[298,304,310,316],"Avash":[299],"Das":[300],"Mr.":[305],"GUPTA":[306],"Prof.":[311],"KUMAR":[312],"Roy":[318,337,356,374,385],"received":[320,339,358,387],"personal":[321,340,359],"compensation":[322,341,360],"range":[325,344,363],"$500-$4,999":[327,346,365],"for":[328,333,347,352,366,371,394],"serving":[329,348,367],"Consultant":[332,351,370],"Alexion":[334],"Pharmaceuticals.":[335,354],"Takeda":[353],"argenx.":[372],"stock":[376],"Cabaletta":[378],"bio.":[379],".":[380],"institution":[382],"research":[388],"support":[389],"from":[390],"Martin":[391],"Shubik":[392],"Fund":[393],"IBM":[395],"at":[396],"Yale":[397],"University.":[398]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2025-10-10T00:00:00"}